Company profile: Avid Radiopharmaceuticals
1.1 - Company Overview
Company description
- Provider of molecular imaging agents to aid detection and monitoring of chronic human diseases. Products include FDA-approved PET imaging agents: Amyvid for detecting beta-amyloid plaques in the brain and Tauvid for detecting tau pathology in patients evaluated for Alzheimer's disease. Based in Philadelphia, PA.
Products and services
- Molecular Imaging Agent Development: Engineers new molecular imaging agents to aid medical management of chronic human diseases by identifying the first stages of pathological change, molecular-level
- Tauvid: A PET imaging agent approved by the FDA that detects tau pathology in patients evaluated for Alzheimer’s disease
- Amyvid: A PET imaging agent approved by the FDA for detecting beta-amyloid plaques in the brain
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Avid Radiopharmaceuticals
Vanda Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies focused on central nervous system disorders, developing and commercializing innovative products through clinical and commercial stage programs, including HETLIOZAccess: an expanded access program for Non-24-Hour Sleep-Wake Disorder (Non-24).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vanda Pharmaceuticals company profile →
Gilgamesh Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel psychotropic and psychedelic-inspired medicines for depression, bipolar depression, anxiety, stress-related disorders, and other conditions, developing compounds optimized for safety, tolerability, duration, and efficacy, including GM-1020 (oral, rapid-acting, non-dissociative NMDAR antagonist for potential at-home use), GM-2505 (short-acting 5-HT2A agonist), GM-5022 (non-hallucinogenic neuroplastogen), and GM-3009 (safer ibogaine analog for opioid use disorder, PTSD, and TBI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gilgamesh Pharmaceuticals company profile →
Satsuma Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development for migraine, advancing STS101, a drug-device combination featuring a proprietary dry-powder formulation of dihydroergotamine (DHE) for the acute treatment of migraine, self-administered via a pre-filled, single-use nasal delivery device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Satsuma Pharmaceuticals company profile →
Grass Technologies
HQ: United States
Website
- Description: Provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders; designs and develops leading-edge products in neurology and other life science markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Grass Technologies company profile →
Convergence Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of novel analgesics for the treatment of chronic pain. An independent biotechnology company focused on developing therapies with potentially commercially attractive efficacy, responder-rate, and side effect profiles. Formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline (GSK).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Convergence Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Avid Radiopharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Avid Radiopharmaceuticals
2.2 - Growth funds investing in similar companies to Avid Radiopharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Avid Radiopharmaceuticals
4.2 - Public trading comparable groups for Avid Radiopharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →